Level of heat-stable thiols in patients with a malignant tumor;Určení hladiny termostabilních thiolů u pacientů se zhoubným nádorem

Klinicka Onkologie

Volumn 20, Issue 6, 2007, Pages 384-389

  Fabrik, I ^a   Adam, V ^a   Krizkova S ^a   Kukacka J ^b   Prusa R ^b   Trnkova L ^c   Kizek, Rene ^a  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Blood; Breast neoplasms; Electrochemistry; Proteins

Indexed keywords

METALLOTHIONEIN; THIOL DERIVATIVE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TRANSPORT; THERMOSTABILITY;

EID: 37249086553     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kowaltowski A J, Vercesi A E. Mitochondrial damage induced by conditions of oxidative stress. Free Radic. Biol. Med. 1999;26(3-4):463-471.
2. Squadrito G L, Pryor W A. Oxidative chemistry of nitric oxide: The roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic. Biol. Med. 1998;25(4-5):392-403.
3. Sen C K, Packer L. Antioxidant and redox regulation of gene transcription. Faseb J. 1996;10(7):709-720.
4. Gilbert H F. Molecular and Cellular Aspects of Thiol Disulfide Exchange. Adv. Enzymol. Relat. Areas Mol. Biol. 1990;63:69-172.
5. Barron E S G. Thiol Groups of Biological Importance. Adv. Enzymol. Relat. Subjects Biochem. 1951;11(201-266.
6. Helbock H J, Beckman K B, Shigenaga M K, et al. DNA oxidation matters: The HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc. Natl. Acad. Sci. U. S. A. 1998;95(1):288-293.
7. Michaels M L, Cruz C, Grollman A P, et al. Evidence That Muty and Mutm Combine to Prevent Mutations by an Oxidatively Damaged Form of Guanine in DNA. Proc. Natl. Acad. Sci. U. S. A. 1992;89(15):7022-7025.
8. Tchou J, Kasai H, Shibutani S, et al. 8-Oxoguanine(8-Hydroxyguanine) DNA Glycosylase and Its Substrate-Specificity. Proc. Natl. Acad. Sci. U. S. A. 1991;88(11):4690-4694.
9. Hopkins F G. On an autoxidisable constituent of the cell. Biochem. J. 1921;15(2):286-305.
10. Meister A, Anderson M E. Glutathione. Annu. Rev. Biochem. 1983;52:711-760.
11. Hurnanen D, Chan H M, Kubow S. The protective effect of metallothionein against lipid peroxidation caused by retinoic acid in human breast cancer cells. J. Pharmacol. Exp. Ther. 1997;283(3):1520-1528.
12. Fan L Z, Cherian M G. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br. J. Cancer 2002;87(9):1019-1026.
13. Zelena J, Potesil D, Vacek J, et al. Metalothionein jako prognostický marker nádorového onemocnění. Klinická Onkologie 2004;17(6):190-195.
14. Petrlova J, Blastik O, Prusa R, et al. Analýza obsahu metatothioneinu u pacientů se zhoubným nádorem prsu, tlustého střeva a nebo melanomem. Klinická Onkologie 2006;19(2):138-142.
15. Kukacka J, Vajtr D, Huska D, et al. Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury. Neuroendocrinol. Lett. 2006;27(Suppl. 2):116-120.
16. Petrlova J, Potesil D, Mikelova R, et al. Attomole voltammetric determination of metallothionein. Electrochim. Acta 2006;51(24):5112-5119.
17. Reid A, Pereira H, Galea M, et al. Metallothionein Expression in Human Breast-Cancer. J. Pathol. 1992;168(Suppl. S):A100-A100.
18. Goulding H, Jasani B, Pereira H, et al. Metallothionein Expression in Human Breast-Cancer. Br. J. Cancer 1995;72(4):968-972.
19. Nadji M, Fresno M, Herrera A, et al. Metallothionein Is a Predictor of Tumor Aggressiveness in Node-Negative Breast-Cancer. Lab. Invest. 1994;70(1):A19-A19.
20. Ioachim E, Kamina S, Demou A, et al. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, p53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res. 1999;19(3A):2133- 2139.
21. Florianczyk B, Grzybowska L. Metallothionein and zinc level in breast cancer. J. Tumor Marker Oncol. 1999;14(4):23-27.
22. Ioachim E, Tsanou E, Briasoulis E, et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 2003;12(2):111-119.
23. Bay B H, Jin R X, Huang J X, et al. Metallothionein as a prognostic biomarker in breast cancer. Exp. Biol. Med. 2006;231(9):1516-1521.
24. Popiela T J, Rudnicka-Sosin L, Dutsch-Wicherek M, et al. The metallothionein and RCAS1 expression analysis in breast cancer and adjacent tissue regarding the immune cells presence and their activity. Neuroendocrinol. Lett. 2006;27(6):786-794.
25. Oyama T, Takei H, Hikino T, et al. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 1996;53(2):112-117.
26. Jin R, Bay B H, Chow V T K, et al. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br. J. Cancer 2000;83(3):319-323.
27. Barnes N L, Ackland M L, Cornish EJ. Metallothionein isoform expression by breast cancer cells. Int J. Biochem. Cell Biol. 2000;32(8):895-903.
28. Sens M A, Beall C L, Sens D A. Metallothionein isoform 3 (MT-3) expression in breast cancer. Mod. Pathol. 2001;14(1):36A-36A.
29. Sens M A, Beall C L, Sens D A. Metallothionein isoform 3 (MT-3) expression in breast cancer. Lab. Invest. 2001;81(1):36A-36A.
30. Tai S K, Tan O J K, Chow V T K, et al. Differential expression of metallothionein 1 and 2 Isoforms in breast cancer lines with different invasive potential - Identification of a novel nonsilent metallothionein-1H mutant variant. Am. J. Pathol. 2003;163(5):2009-2019.
31. Jin R X, Chow V T K, Tan P H, et al. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002;23(1):81-86.
32. Sens M A, Gurel V, Somji S, et al. Metallothionein isoform 3 (MT-3) inhibits growth and increases chemotherapeutic drug resistance of breast cancer cells. Mod. Pathol. 2002;15(1):51A-51A.
33. Sens M A, Gurel V, Somji S, et al. Metallothionein isoform 3 (MT-3) inhibits growth and increases chemotherapeutic drug resistance of breast cancer cells. Lab. Invest. 2002;82(1):51A-51A.
34. Surowiak P, Paluchowski P, Dziegiel P, et al. Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation. Med. Sci. Monitor 2004;10(8):BR300-BR305.
35. Brazdova M, Kizek R, Havran L, et al. Determination of glutathione-S-transferase traces in preparations of p53 C-terminal domain (aa320-393). Bioelectrochemistry 2002;55(1-2):115-118.
36. Geryk E, Kolcova V, V. M. Vývoj epidemiologických ukazatelů zhoubného nádory prsu. Klinická Onkologie 1994;7(1):14-22.
37. Skovajsova M, H. B, Danes J. Screening nádorů prsu v České republice. Klinická Onkologie 2004;17(2):46-48.
38. Janku F, Srovnal J, Korinkova G, et al. Detekce minimální residuální choroby v kostní dřeni pacientek s časným karcinomem prsu technikou kvantitativní RT-PCR v reálném čase pro karcinoembryonální antigen. Klinická Onkologie 2006;19(1):15-18.
39. Simickova M, Petrakova K, Pecen L, et al. Prediktivní význam sérového HER-2/neu u nemocných s karcinomem prsu léčených Herceptinem. Klinická Onkologie 2005;18(1):23-26.
40. Vaclavikova R, Hubackova M, Kubala E, et al. Exprese genu mnohočetné lékové rezistence 1 (mdr1) a její význam v rozvoji a terapii karcinomu prsu. Klinická Onkologie 2007;20(3):253-259.
41. Sopkova B. Prognostické faktory karcinomu prsu. Klinická Onkologie 1988;1(3):92-94.